Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (imrt) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (hnscc): gortec 2004-01 randomized phase iii trial

HIGHLIGHTS

• who: Yungan Tao from the Institut Claudius Regaud, ToulouseClermont-Ferrand, France have published the Article: Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial, in the Journal: (JOURNAL) of 27/01/2020
• what: The widespread use of IMRT after the trial was launched for LA-HNSCC patients was the main reason for slow enrollment and early closure of trial. The first reason is use of cisplatin in both arms.
• how: In this . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.